NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Columbia Property Trust, Inc. (NYSE:CXP), Dr Pepper Snapple Group, Inc. (NYSE:DPS), Immune Pharmaceuticals Inc. (NASDAQ:IMNP), Air Products and Chemicals, Inc. (NYSE:APD), Box, Inc. (NYSE:BOX), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

The new research reports from Fundamental Markets, available for free download at the links above, examine  Columbia Property Trust, Inc. (NYSE:CXP), Dr Pepper Snapple Group, Inc. (NYSE:DPS), Immune Pharmaceuticals Inc. (NASDAQ:IMNP), Air Products and Chemicals, Inc. (NYSE:APD), Box, Inc. (NYSE:BOX), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

For the three months ended June 30, 2017 vs June 30, 2016, Dr Pepper Snapple reported revenue of $1,797 vs $1,695 (up 6.0%), diluted earnings per share $1.02 vs $1.39 (down 26.6%), and dividends per share $0.58 vs $0.53 (up 9.4%). For the twelve months ended December 31, 2016 vs December 31, 2015, Dr Pepper Snapple reported revenue of $6,440 vs $6,282 (up 2.5%), diluted earnings per share $4.54 vs $3.97 (up 14.4%), and dividends per share $2.12 vs $1.92 (up 10.4%).

For the three months ended June 30, 2017 vs June 30, 2016, Air Products and Chemicals reported revenue of $2,121.9 vs $1,914.5 (up 10.8%), diluted earnings per share $0.46 vs $1.59 (down 71.1%), and dividends per share $0.95 vs $0.86 (up 10.5%). For the twelve months ended December 31, 2016 vs December 31, 2015, Air Products and Chemicals reported revenue of $9,524 vs $9,895 (down 3.7%), diluted earnings per share $2.89 vs $5.88 (down 50.9%), and dividends per share $3.39 vs $3.20 (up 5.9%).

For the three months ended July 31, 2017 vs July 31, 2016, Box reported revenue of $122.9 vs $95.7 (up 28.4%), diluted earnings per share -$0.30 vs -$0.30. For the twelve months ended January 31, 2017 vs January 31, 2016, Box reported revenue of $398.6 vs $302.7 (up 31.7%), diluted earnings per share -$1.19 vs -$1.67. Box is expected to report earnings on 11/29/2017. The report will be for the fiscal Quarter ending October 2017. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is -$0.29. The reported EPS for the same quarter last year was -$0.30.

For the three months ended June 30, 2017 vs June 30, 2016, ACADIA Pharmaceuticals reported revenue of $30.5 vs $0.097 (up 31,343.3%), diluted earnings per share -$0.55 vs -$0.63. For the twelve months ended December 31, 2016 vs December 31, 2015, ACADIA Pharmaceuticals reported revenue of $17.3 vs $0.061 (up 28,260.7%), diluted earnings per share -$2.34 vs -$1.63. ACADIA Pharmaceuticals is expected to report earnings on 11/06/2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is -$0.63. The reported EPS for the same quarter last year was -$0.61.

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade—and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.